4-[4-(4-{6-[(2R)-2,3-dihydroxy-1-propoxy]pyridin-2-yl }-3-methylphenyl)piperidin-1-ylsulphonyl]-tetrahydro-2H-pyran-4-carboxylic acid | 312931-65-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[4-(4-{6-[(2R)-2,3-dihydroxy-1-propoxy]pyridin-2-yl }-3-methylphenyl)piperidin-1-ylsulphonyl]-tetrahydro-2H-pyran-4-carboxylic acid
• 英文别名: 4-[4-[4-[6-[(2R)-2,3-dihydroxypropoxy]pyridin-2-yl]-3-methylphenyl]piperidin-1-yl]sulfonyloxane-4-carboxylic acid
• CAS: 312931-65-0
• 化学式: C₂₆H₃₄N₂O₈S
• 分子量: 534.631
• InChiKey: XWXNNLROARBENJ-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  155
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• Composition for the treatment of damaged tissue
  申请人：Pfizer Inc.

  公开号：US20030199440A1

  公开（公告）日：2003-10-23

  A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.

  描述了一种用于受损组织，如伤口治疗（例如愈合）的药物。该药物包括包含以下成分的组合物：（a）生长因子；和（b）抑制剂；以及可选的（c）药用载体、稀释剂或赋形剂；其中抑制剂可以抑制至少一种在受损组织，如伤口环境中上调的特定不良蛋白质（例如特定蛋白酶）的作用。
• METALLOPROTEASE INHIBITORS
  申请人：Pfizer Limited

  公开号：EP1181017B1

  公开（公告）日：2003-04-16
• COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE
  申请人：Pfizer Limited

  公开号：EP1242120A2

  公开（公告）日：2002-09-25
• US6511993B1
  申请人：——

  公开号：US6511993B1

  公开（公告）日：2003-01-28
• [EN] COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUE<br/>[FR] COMPOSITION POUR LE TRAITEMENT DE TISSU LESE
  申请人：PFIZER LTD

  公开号：WO2001049309A2

  公开（公告）日：2001-07-12

  A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.